JPMorgan Chase & Co. raised its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 111.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 398,738 shares of the company's stock after buying an additional 210,354 shares during the period. JPMorgan Chase & Co. owned about 0.33% of Privia Health Group worth $7,795,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in PRVA. First Horizon Advisors Inc. grew its position in Privia Health Group by 53.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock valued at $35,000 after purchasing an additional 632 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Privia Health Group by 7,833.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock valued at $47,000 after acquiring an additional 2,350 shares during the last quarter. Financial Management Professionals Inc. bought a new stake in Privia Health Group in the fourth quarter worth approximately $51,000. Nisa Investment Advisors LLC lifted its stake in shares of Privia Health Group by 185.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company's stock valued at $98,000 after purchasing an additional 3,249 shares during the last quarter. Finally, KBC Group NV increased its position in Privia Health Group by 48.1% during the fourth quarter. KBC Group NV now owns 5,012 shares of the company's stock worth $98,000 after buying an additional 1,627 shares during the last quarter. Institutional investors and hedge funds own 94.48% of the company's stock.
Privia Health Group Price Performance
Privia Health Group stock opened at $23.87 on Thursday. The business has a 50 day simple moving average of $23.83 and a 200 day simple moving average of $21.59. Privia Health Group, Inc. has a one year low of $15.92 and a one year high of $26.04. The company has a market capitalization of $2.90 billion, a PE ratio of 238.72, a price-to-earnings-growth ratio of 3.47 and a beta of 0.88.
Analyst Ratings Changes
PRVA has been the topic of a number of recent analyst reports. Barclays raised their price objective on Privia Health Group from $21.00 to $23.00 and gave the company an "equal weight" rating in a research note on Thursday, April 10th. Truist Financial raised their price target on Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Needham & Company LLC reissued a "buy" rating and set a $30.00 price objective on shares of Privia Health Group in a research report on Thursday, April 10th. Robert W. Baird increased their target price on Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a research note on Tuesday. Finally, JMP Securities set a $29.00 price objective on shares of Privia Health Group in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Privia Health Group presently has a consensus rating of "Buy" and an average target price of $27.00.
Check Out Our Latest Research Report on PRVA
Insider Buying and Selling at Privia Health Group
In other news, CFO David Mountcastle sold 5,630 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total value of $125,999.40. Following the transaction, the chief financial officer now directly owns 179,676 shares of the company's stock, valued at $4,021,148.88. The trade was a 3.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 14.20% of the company's stock.
Privia Health Group Company Profile
(
Free Report)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Featured Stories
Want to see what other hedge funds are holding PRVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Privia Health Group, Inc. (NASDAQ:PRVA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Privia Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.
While Privia Health Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
